Business News • PR NewsWire • SciTech Development, LLC Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma

SciTech Development, LLC Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma

SciTech Development, LLC Announces FDA Acceptance of Investigational New Drug (IND) Application for ST-001 nanoFenretinide in Patients with T-Cell Lymphoma

GROSSE POINTE FARMS, Mich., Dec. 23, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has accepted SciTech Development's Investigational New Drug (IND) Application for ST-001 nanoFenretinide, an experimental treatment for T-cell non-Hodgkin's lymphoma (NHL). The FDA...

View More : https://www.prnewswire.com:443/news-releases/scitech-development-llc-announces-fda-acceptance-of-investigational-new-dru...

Releted News by prnewswire

Enlight Renewable Energy Ltd. Has Completed a Substantial Stock Issuance, Raising NIS 358 Million

On the 2019 Annual Commendation Conference, ALLPCB Expounded Its 2.0 Development Strategy

Boeing Announces Leadership Changes

Fundstrat appoints Brian Rauscher Head of Global Portfolio Strategy and Asset Allocation, Managing Director

Spring Sale Fever at the 25th China (Guzhen) International Lighting Fair (Spring Edition), in March, 2020